Skip to main content

Peer Review reports

From: A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial

Original Submission
28 Mar 2011 Submitted Original manuscript
5 Jul 2011 Reviewed Reviewer Report - Stephen Clarke
29 Jul 2011 Author responded Author comments - Clemens Giessen
Resubmission - Version 2
29 Jul 2011 Submitted Manuscript version 2
20 Aug 2011 Author responded Author comments - Clemens Giessen
Resubmission - Version 3
20 Aug 2011 Submitted Manuscript version 3
Publishing
23 Aug 2011 Editorially accepted
23 Aug 2011 Article published 10.1186/1471-2407-11-367

You can find further information about peer review here.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us